Edward Damrose

Prof. Edward Damrose

Stanford University
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
JAJohn R. de Almeida
John R. de Almeida
RLRyan Li
Ryan Li
JMJ. Scott Magnuson
J. Scott Magnuson
RSRichard V. Smith
Richard V. Smith
EMEric Moore
Eric Moore
FHF. Christopher Holsinger
F. Christopher Holsinger
Large patient cohorts are necessary to validate the efficacy of transoral robotic surgery (TORS) in the management of head and neck cancer. To review oncologic outcomes of TORS from a large multi-institutional collaboration and to identify predictors of disease recurrence and disease-specific mortality. A retrospective review of records from 410 patients undergoing TORS for laryngeal and pharyngeal cancers from January 1, 2007, through December 31, 2012, was performed. Pertinent data were obtained from 11 participating medical institutions. Select patients received radiation therapy and/or chemotherapy before or after TORS. Locoregional control, disease-specific survival, and overall survival were calculated. We used Kaplan-Meier survival analysis with log-rank testing to evaluate individual variable association with these outcomes, followed by multivariate analysis with Cox proportional hazards regression modeling to identify independent predictors. Of the 410 patients treated with TORS in this study, 364 (88.8%) had oropharyngeal cancer. Of these 364 patients, information about post-operative adjuvant therapy was known about 338: 106 (31.3) received radiation therapy alone, and 72 (21.3%) received radiation therapy with concurrent chemotherapy. Neck dissection was performed in 323 patients (78.8%). Mean follow-up time was 20 months. Local, regional, and distant recurrence occurred in 18 (4.4%), 15 (3.7%), and 10 (2.4%) of 410 patients, respectively. Seventeen (4.1%) died of disease, and 13 (3.2%) died of other causes. The 2-year locoregional control rate was 91.8% (95% CI, 87.6%-94.7%), disease-specific survival 94.5% (95% CI, 90.6%-96.8%), and overall survival 91% (95% CI, 86.5%-94.0%). Multivariate analysis identified improved survival among women (P = .05) and for patients with tumors arising in tonsil (P = .01). Smoking was associated with worse overall all-cause mortality (P = .01). Although advanced age and tobacco use were associated with locoregional recurrence and disease-specific survival, they, as well as tumor stage and other adverse histopathologic features, did not remain significant on multivariate analysis. This large, multi-institutional study supports the role of TORS within the multidisciplinary treatment paradigm for the treatment of head and neck cancer, especially for patients with oropharyngeal cancer. Favorable oncologic outcomes have been found across institutions. Ongoing comparative clinical trials funded by the National Cancer Institute will further evaluate the role of robotic surgery for patients with head and neck cancers.

1 January 2008 in Medical Hypotheses
Verified
Journal Article
Closed access
EDEdward Damrose
Edward Damrose

1 December 2004 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
ACAlen N. Cohen
Alen N. Cohen
EDEdward Damrose
Edward Damrose
RHRobert Y. Huang
Robert Y. Huang
SNScott D. Nelson
Scott D. Nelson
KBKeith E. Blackwell
Keith E. Blackwell
TCThomas C. Calcaterra
Thomas C. Calcaterra

1 February 2009 in Auris Nasus Larynx
Verified
Journal Article
Closed access
EDEdward Damrose
Edward Damrose


1 November 2000 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
RHRobert Y Huang
Robert Y Huang
EDEdward Damrose
Edward Damrose
KBKeith E Blackwell
Keith E Blackwell
ACAlen N Cohen
Alen N Cohen
TCThomas C Calcaterra
Thomas C Calcaterra